Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
Advances in mast cell tumour diagnosis and therapy
Mast cell tumours are one of the most common tumours of the canine skin and have a reputation for being difficult to manage because of their variable clinical presentation, behaviour and response to treatment. The stem cell factor receptor KIT seems to play a central role in the aetiology, as recent studies showed - which might offer new therapeutic options in the future.

This review of recent literature on canine mast cell tumours suggests that the majority of such tumours may not be as bad as their reputation suggests. Most grade I and grade II tumours can be managed successfully by good surgery. Recent literature also calls into question the utility of clinical staging systems and the value of assessing surgical margins for prognosis and highlights the paucity of well-conducted, case-controlled clinical trials in assessing the efficacy of medical management of high-risk tumours. In terms of more basic research, recent studies have implicated the stem cell factor receptor KIT as having a role in the aetiology of canine mast cell tumours and there appears to be an association between c-kit mutation and higher grade of tumour. This may offer a possible target for new therapeutic approaches.

Source: J. M. Dobson, T. J. Scase (2007):
Advances in the diagnosis and management of cutaneous mast cell tumours in dogs. In:
Journal of Small Animal Practice 48 (8), 424–431.


Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

Patient-specific facemask to facilitate brain biopsymembers
The objective of this pilot study was to describe the application and first preliminary data of a novel MRI and CT compatible patient-specific facemask for stereotactic brain biopsy of intracranial lesions in dogs. Five client-owned dogs presenting for neurological deficits consistent with forebrain disease were included in the study. All dogs had MRI findings consistent with an intracranial lesion. But biopsies in this region are not easy to obtain. Does an individual face mask help?

  • Critically ill dogs and their immune function
  • RET-He to diagnose iron-deficient erythropoiesis in dogsmembers
  • Hypertriglyceridemia-Associated Proteinuria in Miniature Schnauzersmembers
  • Gastrointestinal dysmotility disorders in critically ill animalsmembers
  • Disorder of sex development in a cat with chromosome mosaicism members
  • Generalized discoid lupus erythematosus in dogs members
  • Epidermolysis bullosa acquisita in dogsmembers
  • Chiari-Like Malformation and Syringomyelia in American Brussels Griffon Dogsmembers
  • Efficacy and Potential Complications of Transjugular Liver Biopsymembers
  • Hypomagnesemia in Brachycephalic Dogsmembers
  • Comparison of two minimally invasive techniques for liver biopsy members
  • Topical aqueous sirolimus and the tear production members


  • [ Home ] [ About ] [ Contact / Request ][ Disclaimer ]

    Copyright © 2001-2016 VetContact GmbH
    All rights reserved